|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 458.12 USD | -1.55% |
|
+1.53% | +94.69% |
| 12-03 | Alnylam Pharmaceuticals Announces Changes to Board of Directors | CI |
| 12-03 | Alnylam Pharmaceuticals announces changes to board of directors | RE |
| Capitalization | 60.52B 52.03B 48.74B 45.43B 83.91B 5,447B 91.26B 570B 220B 2,573B 227B 222B 9,406B | P/E ratio 2025 * |
200x | P/E ratio 2026 * | 64.7x |
|---|---|---|---|---|---|
| Enterprise value | 58.9B 50.63B 47.43B 44.21B 81.65B 5,301B 88.81B 555B 214B 2,503B 221B 216B 9,154B | EV / Sales 2025 * |
15.7x | EV / Sales 2026 * | 10.8x |
| Free-Float |
99.2% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Alnylam Pharmaceuticals, Inc.
| 1 day | -1.55% | ||
| 1 week | +1.53% | ||
| Current month | +1.53% | ||
| 1 month | +5.42% | ||
| 3 months | +1.35% | ||
| 6 months | +48.74% | ||
| Current year | +94.69% |
| 1 week | 448.26 |  | 479.79 |
| 1 month | 420.3 | | 479.79 |
| Current year | 205.87 | | 495.55 |
| 1 year | 205.87 | | 495.55 |
| 3 years | 141.98 | | 495.55 |
| 5 years | 117.58 | | 495.55 |
| 10 years | 31.38 | | 495.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 2021-12-31 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 57 | 2019-08-12 |
| Chief Tech/Sci/R&D Officer | - | 2023-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 79 | 2012-04-22 |
Amy Schulman
CHM | Chairman | 64 | 2023-01-04 |
David Pyott
BRD | Director/Board Member | 71 | 2015-12-17 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 5.08% | 1 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.55% | +1.53% | +81.93% | +102.53% | 60.52B | |
| -0.41% | -6.06% | +22.37% | +173.58% | 905B | |
| -0.27% | -2.41% | +35.05% | +12.95% | 487B | |
| -1.15% | -0.71% | +28.33% | +37.90% | 400B | |
| +0.26% | +1.14% | +21.30% | +0.44% | 330B | |
| +0.58% | -2.73% | +28.01% | +20.71% | 281B | |
| +0.19% | +2.49% | +18.48% | +24.80% | 255B | |
| -1.16% | -4.87% | -3.70% | -9.35% | 248B | |
| +1.24% | -2.33% | -59.84% | -31.25% | 214B | |
| -3.02% | -4.51% | +20.25% | +15.79% | 178B | |
| Average | -0.34% | -1.85% | +19.22% | +34.81% | 335.7B | |
| Weighted average by Cap. | -0.12% | -2.71% | +18.78% | +56.82% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.74B 3.22B 3.01B 2.81B 5.19B 337B 5.64B 35.25B 13.61B 159B 14.05B 13.75B 582B | 5.35B 4.6B 4.3B 4.01B 7.41B 481B 8.06B 50.35B 19.44B 227B 20.06B 19.64B 831B |
| Net income | 304M 261M 245M 228M 421M 27.35B 458M 2.86B 1.11B 12.92B 1.14B 1.12B 47.23B | 963M 828M 775M 723M 1.33B 86.67B 1.45B 9.07B 3.5B 40.93B 3.61B 3.54B 150B |
| Net Debt | -1.63B -1.4B -1.31B -1.22B -2.25B -146B -2.45B -15.32B -5.91B -69.12B -6.1B -5.97B -253B | -3.04B -2.61B -2.45B -2.28B -4.21B -274B -4.58B -28.63B -11.05B -129B -11.41B -11.16B -472B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 458.12 $ | -1.55% | 627,353 |
| 25-12-04 | 465.34 $ | -1.68% | 983,982 |
| 25-12-03 | 473.29 $ | +1.80% | 1,092,993 |
| 25-12-02 | 464.93 $ | +2.28% | 1,204,115 |
| 25-12-01 | 454.56 $ | +0.74% | 1,070,657 |
Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALNY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition